Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.
about
Production of glycoprotein vaccines in Escherichia coliStructures of synthetic O-antigen fragments from serotype 2a Shigella flexneri in complex with a protective monoclonal antibodyDipstick test for rapid diagnosis of Shigella dysenteriae 1 in bacterial cultures and its potential use on stool samplesA capsule conjugate vaccine approach to prevent diarrheal disease caused by Campylobacter jejuni.Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model.Simple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines.Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar TyphimuriumThe genome of Shigella dysenteriae strain Sd1617 comparison to representative strains in evaluating pathogenesis.Shigella flexneri infection: pathogenesis and vaccine development.Broadly protective Shigella vaccine based on type III secretion apparatus proteins.O-Acetylation in the O-specific polysaccharide isolated from Shigella flexneri serotype 2aVaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.Vaccines based on the cell surface carbohydrates of pathogenic bacteria.Live-attenuated Shigella vaccines.Expression of Shigella flexneri ipaB Gene in Tobacco.Shigella Vaccine Development: Finding the Path of Least Resistance.Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.Inactivated and subunit vaccines to prevent shigellosis.Recent progress towards development of a Shigella vaccine.Increased efficiency of Campylobacter jejuni N-oligosaccharyltransferase PglB by structure-guided engineering.Reaching a consensus on management practices and vaccine development targets for mitigation of infectious diarrhoea among deployed US military forces.Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli.Conformational studies of the O-specific polysaccharide of Shigella flexneri 5a and of four related synthetic pentasaccharide fragments using NMR and molecular modeling.Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease.Synthesis of two linear PADRE conjugates bearing a deca- or pentadecasaccharide B epitope as potential synthetic vaccines against Shigella flexneri serotype 2a infection.Activities of aqueous extracts of Mallotus oppositifolium on Shigella dysenteriae A1-induced diarrhoea in rats.An Approach to Identify and Characterize a Subunit Candidate Shigella Vaccine Antigen.Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Shigella Serum Bactericidal Assay.
P2860
Q24628546-7722919A-AFB7-4701-8305-4D81914E0CA2Q27651173-875782B0-4249-4F90-BEB3-92500393A31EQ28744352-98D1463B-C922-4CB6-A919-2566FE35081EQ33577932-9657B2A7-06AF-47A0-877F-C1885639FBA2Q33983350-F48620A3-7E2B-4853-A184-1758CF445619Q34214205-5F0F6CFE-F506-4E8B-8253-EC8179FBA0FCQ35098175-30E27B7B-72E5-49A1-9BF9-7327D184FA9BQ35651224-94518ECB-B1F1-466F-B5BD-8D1687E3269BQ35671854-4F4E0312-E7C9-41AD-9A3F-15005C7DD1E8Q35805439-32EAE464-1B7E-4621-ADCB-DFAC8802AE61Q35828313-ABEA4E36-78F5-4F53-BC5F-BCE69A70C97CQ35887055-791E1B4B-FA0E-4A07-8874-4F3DA1282666Q36128243-E64F97D8-3963-4CBB-A802-5D344624FA94Q36689023-E9E0A3EB-79E0-48FF-93A1-4EB0B892B310Q36946812-ED1D8649-51D9-40C5-AF19-738D967B9C37Q37477191-E69FC79A-21E0-41C6-A758-AC227A872751Q37477196-793BC63B-BFF0-4042-840E-D6DBCABDC981Q37640115-5F6AC555-B7A9-4076-A903-C5A250AC1376Q38068954-A799CDC4-2DD0-42FF-9652-3F1C4A808AB5Q38300058-5941755C-3DDE-48F4-A1C1-4FBC1F0C5265Q39397885-8BBC6C9B-D7BA-4632-9082-7817A2EB6AE6Q41008205-8C2E708E-3314-4BC4-BF73-B5F45DE2680BQ44553718-31683942-5987-4D32-AD07-9972F143C29EQ44891342-C98D9377-181F-483C-BD5F-43E773D158E9Q45237263-36D002BB-527C-464E-861F-BAA89FF2FACBQ46157459-A5DA09E7-5FB2-4398-AD70-765163F68795Q52875091-0735397B-C312-4843-8136-E8467BE59E09Q55333715-74117D09-5F4E-415F-9870-F8CC8EB1EE84
P2860
Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Safety and immunogenicity of i ...... vaccines in adults in Israel.
@ast
Safety and immunogenicity of i ...... vaccines in adults in Israel.
@en
Safety and immunogenicity of i ...... vaccines in adults in Israel.
@nl
type
label
Safety and immunogenicity of i ...... vaccines in adults in Israel.
@ast
Safety and immunogenicity of i ...... vaccines in adults in Israel.
@en
Safety and immunogenicity of i ...... vaccines in adults in Israel.
@nl
prefLabel
Safety and immunogenicity of i ...... vaccines in adults in Israel.
@ast
Safety and immunogenicity of i ...... vaccines in adults in Israel.
@en
Safety and immunogenicity of i ...... vaccines in adults in Israel.
@nl
P2093
P2860
P1476
Safety and immunogenicity of i ...... vaccines in adults in Israel.
@en
P2093
J B Robbins
J H Passwell
J Shiloach
P2860
P304
P356
10.1128/IAI.69.3.1351-1357.2001
P407
P577
2001-03-01T00:00:00Z